A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06030076 · clinicaltrials.gov ↗

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Tildrakizumab

Sponsor

Almirall, S.A.